CapsoVision (CV) Asset Writedowns and Impairment (2024)

CapsoVision (CV) posted Asset Writedowns and Impairment of $7000.0 for Q4 2024, up 600.0% sequentially from $1000.0 in Q3 2024.

CapsoVision (CV) Asset Writedowns and Impairment (2024) Analysis & Trends

CapsoVision has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $7000.0 in Q4 2024.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $7000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $8000.0 (changed N/A YoY) and the FY2025 annual result came in at $11000.0, up 37.5% from the prior year.
Asset Writedowns and Impairment climbed to $7000.0 in Q4 2024 per CV's latest filing, from $1000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $7000.0 in Q4 2024 and troughed at $1000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	CapsoVision	299.87 Mn	290.80 Mn	1.87 Mn

Download Data